In summary, the PI3K-AKT-mTOR cascade is frequently activated in prostate cancer, and genomic profiling has revealed that oncogenic genetic alterations occur within a diverse array of PI3K-AKT-mTOR pathway components. This evidence concerns the gene MTOR and prostate carcinoma.